Targeting drugs to combinations of receptors

A modeling analysis of potential specificity

Michael Caplan, Elena V. Rosca

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Targeting drugs to specific cells by conjugating the drug to an antibody or ligand for a cell surface receptor currently requires that the receptor be uniquely over-expressed by the target cell (the target cell over-expresses a particular receptor in comparison with untargeted cells, which do display this receptor type but a lesser number of them). Here we develop a mathematical model to predict the behavior of multivalent ligand-drug constructs containing two different ligands for two different receptors, which would allow targeting cells that do not uniquely over-express any receptor. In this model, target cells express both receptors at a high level; whereas, untargeted cells express one receptor type at the high level but the other at a lower level. The model predicts that these heterovalent conjugates (containing two different types of ligands) can achieve specificity even when the target cell does not uniquely over-express any one receptor type. Using the current approach, constructs in which only one ligand type is used will bind as much to untargeted cells as to the target cells. Therefore, this combination strategy can enormously expand the number of applications for which cell surface receptor targeting of drugs is an appropriate option.

Original languageEnglish (US)
Pages (from-to)1113-1124
Number of pages12
JournalAnnals of Biomedical Engineering
Volume33
Issue number8
DOIs
StatePublished - Nov 2005

Fingerprint

Ligands
Antibodies
Drug Delivery Systems
Mathematical models

Keywords

  • Biomaterial
  • Drug delivery
  • Mathematical model
  • Multivalent

ASJC Scopus subject areas

  • Biomedical Engineering

Cite this

Targeting drugs to combinations of receptors : A modeling analysis of potential specificity. / Caplan, Michael; Rosca, Elena V.

In: Annals of Biomedical Engineering, Vol. 33, No. 8, 11.2005, p. 1113-1124.

Research output: Contribution to journalArticle

@article{f574b56fc3314a5b990d0f4c4de50fbd,
title = "Targeting drugs to combinations of receptors: A modeling analysis of potential specificity",
abstract = "Targeting drugs to specific cells by conjugating the drug to an antibody or ligand for a cell surface receptor currently requires that the receptor be uniquely over-expressed by the target cell (the target cell over-expresses a particular receptor in comparison with untargeted cells, which do display this receptor type but a lesser number of them). Here we develop a mathematical model to predict the behavior of multivalent ligand-drug constructs containing two different ligands for two different receptors, which would allow targeting cells that do not uniquely over-express any receptor. In this model, target cells express both receptors at a high level; whereas, untargeted cells express one receptor type at the high level but the other at a lower level. The model predicts that these heterovalent conjugates (containing two different types of ligands) can achieve specificity even when the target cell does not uniquely over-express any one receptor type. Using the current approach, constructs in which only one ligand type is used will bind as much to untargeted cells as to the target cells. Therefore, this combination strategy can enormously expand the number of applications for which cell surface receptor targeting of drugs is an appropriate option.",
keywords = "Biomaterial, Drug delivery, Mathematical model, Multivalent",
author = "Michael Caplan and Rosca, {Elena V.}",
year = "2005",
month = "11",
doi = "10.1007/s10439-005-5779-1",
language = "English (US)",
volume = "33",
pages = "1113--1124",
journal = "Annals of Biomedical Engineering",
issn = "0090-6964",
publisher = "Springer Netherlands",
number = "8",

}

TY - JOUR

T1 - Targeting drugs to combinations of receptors

T2 - A modeling analysis of potential specificity

AU - Caplan, Michael

AU - Rosca, Elena V.

PY - 2005/11

Y1 - 2005/11

N2 - Targeting drugs to specific cells by conjugating the drug to an antibody or ligand for a cell surface receptor currently requires that the receptor be uniquely over-expressed by the target cell (the target cell over-expresses a particular receptor in comparison with untargeted cells, which do display this receptor type but a lesser number of them). Here we develop a mathematical model to predict the behavior of multivalent ligand-drug constructs containing two different ligands for two different receptors, which would allow targeting cells that do not uniquely over-express any receptor. In this model, target cells express both receptors at a high level; whereas, untargeted cells express one receptor type at the high level but the other at a lower level. The model predicts that these heterovalent conjugates (containing two different types of ligands) can achieve specificity even when the target cell does not uniquely over-express any one receptor type. Using the current approach, constructs in which only one ligand type is used will bind as much to untargeted cells as to the target cells. Therefore, this combination strategy can enormously expand the number of applications for which cell surface receptor targeting of drugs is an appropriate option.

AB - Targeting drugs to specific cells by conjugating the drug to an antibody or ligand for a cell surface receptor currently requires that the receptor be uniquely over-expressed by the target cell (the target cell over-expresses a particular receptor in comparison with untargeted cells, which do display this receptor type but a lesser number of them). Here we develop a mathematical model to predict the behavior of multivalent ligand-drug constructs containing two different ligands for two different receptors, which would allow targeting cells that do not uniquely over-express any receptor. In this model, target cells express both receptors at a high level; whereas, untargeted cells express one receptor type at the high level but the other at a lower level. The model predicts that these heterovalent conjugates (containing two different types of ligands) can achieve specificity even when the target cell does not uniquely over-express any one receptor type. Using the current approach, constructs in which only one ligand type is used will bind as much to untargeted cells as to the target cells. Therefore, this combination strategy can enormously expand the number of applications for which cell surface receptor targeting of drugs is an appropriate option.

KW - Biomaterial

KW - Drug delivery

KW - Mathematical model

KW - Multivalent

UR - http://www.scopus.com/inward/record.url?scp=23844436235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23844436235&partnerID=8YFLogxK

U2 - 10.1007/s10439-005-5779-1

DO - 10.1007/s10439-005-5779-1

M3 - Article

VL - 33

SP - 1113

EP - 1124

JO - Annals of Biomedical Engineering

JF - Annals of Biomedical Engineering

SN - 0090-6964

IS - 8

ER -